Comparison of Ticagrelor And Clopidogrel on Inflammatory Biomarkers And Vascular Endothelial Function

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 350 participants.

Also called NCT02123004

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 350 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02123004
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02123004. Randomized; no masking; primary purpose treatment. Start 2014-04 (registry gives no type); primary completion 2016-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of Ticagrelor And Clopidogrel on Inflammatory Biomarkers And Vascular Endothelial Function
Acronym
TIGERCAVE
Condition
ST-Segment Elevation Myocardial Infarction
Intervention (Drug)
Ticagrelor
Intervention (Drug)
Clopidogrel
Lead sponsor
Jinan Central Hospital (class: other)

Record details

Record id
cardio:ct-nct02123004
Content hash
54be69522fe8748daf5496e335948b31c3947c2698ea132ba7bac8eeecd92d16